[10]‐Gingerol Reverts Malignant Phenotype of Breast Cancer Cells in 3D Culture. Issue 9 (15th May 2017)

• Record Type: Journal Article
• Authors: Fuzer, Angelina M.; Lee, Sun‐Young; Mott, Joni D.; Cominetti, Marcia R.
• Is Part Of: Journal of cellular biochemistry. Volume 118:Issue 9(2017)
• Page Start: 2693
• Page End: 2699
• Publication Date: 2017-05-15
• Subjects: 3D CULTURE -- [10]‐GINGEROL -- BREAST CANCER -- LAMININ‐RICH EXTRACELLULAR MATRIX -- MICROENVIRONMENT -- NATURAL PRODUCTS; Cytochemistry -- Periodicals; 572
• DOI: 10.1002/jcb.25906
• Languages: English
• ISSNs: 0730-2312

Abstract

ABSTRACT: Breast cancer is a complex and multifactorial disease. Tumors have a heterogeneous microenvironment, which have multiple interactions with other cell types, greatly influencing the behavior of tumor cells and response to therapy. The 3D culture mimics the microenvironment better found in vivo and is more appropriated than the traditional 2D culture made from plastic to test the cellular response to drugs. To investigate the effects of [10]‐gingerol on breast tumor cells, we used physiologically relevant three‐dimensional (3D) cultures of malignant and non‐malignant human breast cells grown in laminin‐rich extracellular matrix gels (lr‐ECM). Our results showed selective cytotoxicity of [10]‐gingerol against the malignant T4‐2 breast cancer cell line compared to non‐malignant S1 cells. The compound reverted the malignant phenotype of the cancer cells, downregulating the expression of epidermal growth factor receptor (EGFR) and β1‐integrin. Moreover, [10]‐gingerol induced apoptosis in this cell line. These results suggest that [10]‐gingerol may be an effective compound to use as adjuvant therapy in breast cancer treatment. J. Cell. Biochem. 118: 2693–2699, 2017. © 2017 Wiley Periodicals, Inc. Abstract : Malignant T4‐2 cells treated with [10]‐gingerol had a remarkable reduction on 3D structures size, similar to that observed with PD98059 and AIIB2 antibody treatments, suggesting that this natural product has a potential to modulate the malignant phenotype.